Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Selling, General & Admin	11.34	11.16	12.16	13.14	9.15	6.09
Research & Development	41.9	39.42	40.88	34.52	28.31	20.62
Operating Expenses	53.24	50.59	53.04	47.66	37.46	26.71
Operating Income	-53.24	-50.59	-53.04	-47.66	-37.46	-26.71
Interest & Investment Income	6.16	7.32	6.52	0.95	0.03	0.18
Currency Exchange Gain (Loss)	-0.14	0.19	-0.04	-0.9	-0.27	0.13
Other Non Operating Income (Expenses)	0.09	0.08	-0.04	-	0.05	0.15
EBT Excluding Unusual Items	-47.14	-43	-46.6	-47.62	-37.64	-26.26
Other Unusual Items	-	-	-0.9	-	-	-
Pretax Income	-47.14	-43	-47.5	-47.62	-37.64	-26.26
Income Tax Expense	-	-	0.01	0.36	0.27	0.02
Net Income	-47.14	-43	-47.51	-47.98	-37.91	-26.28
Net Income to Common	-47.14	-43	-47.51	-47.98	-37.91	-26.28
Shares Outstanding (Basic)	85	83	80	77	70	58
Shares Outstanding (Diluted)	85	83	80	77	70	58
Shares Change (YoY)	3.60%	4.61%	3.74%	10.18%	19.95%	18.99%
EPS (Basic)	-0.56	-0.52	-0.60	-0.62	-0.54	-0.45
EPS (Diluted)	-0.56	-0.52	-0.60	-0.62	-0.54	-0.45
Free Cash Flow	-29.81	-30.81	-27.79	-24.24	-30.38	-21.29
Free Cash Flow Per Share	-0.35	-0.37	-0.35	-0.32	-0.43	-0.37
EBIT	-53.24	-50.59	-53.04	-47.66	-37.46	-26.71

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q